To check the effect of visual rehabilitatio
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: D3A8- Other benign neuroendocrine tumorsHealth Condition 2: E236- Other disorders of pituitary gland
- Registration Number
- CTRI/2023/08/056030
- Lead Sponsor
- Bharti
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a.) patients with sellar/suprasellar tumor with impaired vision and having visual symptoms.
b.) patients with sellar/suprasellar tumor operated in Nehru, Hospital, PGIMER, CHD
c.) patient those are willing to participate
Exclusion Criteria
a.) sellar/suprasellar tumor patient with other vision problem or disease condition like cataract, blindness, glaucoma etc.
b.) patient with impaired consciousness
c.) patient with pituitary microadenoma or tumor less than 2 cm
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by nurse-led visual rehabilitation in sellar/suprasellar tumor patients post-surgery?
How does nurse-led visual rehabilitation compare to standard-of-care interventions in improving visual outcomes for post-neurosurgery patients with pituitary disorders?
Are there specific biomarkers associated with improved quality of life following visual rehabilitation in patients with neuroendocrine tumors and visual deficits?
What are the potential adverse events linked to visual rehabilitation protocols in neurosurgery patients, and how are they managed?
What combination therapies or alternative approaches are being explored alongside visual rehabilitation for sellar/suprasellar tumor patients in clinical research?